Ongoing studies on acute antithrombotic treatment of adult patients with acute DVT
| Study setting . | Interventions . | Study design . | ClinicalTrials.gov identifier . |
|---|---|---|---|
| Symptomatic isolated distal DVT | Rivaroxaban vs placebo for 6 weeks duration after a standard 6-week treatment with rivaroxaban | Randomized, double-blind | NCT02722447 |
| Isolated calf DVT | Apixaban vs placebo | Phase 4, randomized, double-blind | NCT03590743 |
| Symptomatic acute VTE (proximal lower extremity DVT or segmental or greater PE) | Apixaban vs rivaroxaban | Phase 4, randomized, open-label | NCT03266783 |
| VTE treatment in patients with renal impairment | Apixaban (10 mg twice per day for 7 days followed by 2.5 mg twice per day) or rivaroxaban (15 mg twice per day followed by 15 mg once per day) vs standard of care (LMWH/VKA or UFH/VKA) | Randomized, open-label non-inferiority | NCT02664155 |
| Acute common and/or external iliac or common femoral DVT | Pharmaco-mechanical thrombolysis with or without stenting | Prospective cohort | NCT03901872 |
| Study setting . | Interventions . | Study design . | ClinicalTrials.gov identifier . |
|---|---|---|---|
| Symptomatic isolated distal DVT | Rivaroxaban vs placebo for 6 weeks duration after a standard 6-week treatment with rivaroxaban | Randomized, double-blind | NCT02722447 |
| Isolated calf DVT | Apixaban vs placebo | Phase 4, randomized, double-blind | NCT03590743 |
| Symptomatic acute VTE (proximal lower extremity DVT or segmental or greater PE) | Apixaban vs rivaroxaban | Phase 4, randomized, open-label | NCT03266783 |
| VTE treatment in patients with renal impairment | Apixaban (10 mg twice per day for 7 days followed by 2.5 mg twice per day) or rivaroxaban (15 mg twice per day followed by 15 mg once per day) vs standard of care (LMWH/VKA or UFH/VKA) | Randomized, open-label non-inferiority | NCT02664155 |
| Acute common and/or external iliac or common femoral DVT | Pharmaco-mechanical thrombolysis with or without stenting | Prospective cohort | NCT03901872 |
VKA, vitamin K antagonist.